Skip to main content

A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF ZANZALINTINIB (XL092) IN COMBINATION WITH PEMBROLIZUMAB VS PEMBROLIZUMAB IN THE FIRST-LINE TREATMENT OF SUBJECTS WITH PD-L1 POSITIVE RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCIN

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Exelixis, Inc

Start Date

August 16, 2024

End Date

September 22, 2029
 

Administered By

Duke Cancer Institute

Awarded By

Exelixis, Inc

Start Date

August 16, 2024

End Date

September 22, 2029